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Abstract
Background: Microglia are the resident immune cells of the central nervous system and are accepted to be
involved in a variety of neurodegenerative diseases. Several studies have demonstrated that microglia, like
peripheral macrophages, exhibit two entirely different functional activation states, referred to as classical (M1) and
alternative (M2) activation. TGFβ is one of the most important anti-inflammatory cytokines and its effect on
inhibiting microglia or macrophage classical activation has been extensively studied. However, the role of TGFβ
during alternative activation of microglia has not been described yet.
Methods: To investigate the role of TGFβ in IL4-induced microglia alternative activation, both, BV2 as well as
primary microglia from new born C57BL/6 mice were used. Quantitative RT-PCR and western blots were performed
to detect mRNA and protein levels of the alternative activation markers Arginase1 (Arg1) and Chitinase 3-like 3
(Ym1) after treatment with IL4, TGFβ or both. Endogenous TGFβ release after IL4 treatment was evaluated using the
mink lung epithelial cell (MLEC) assay and a direct TGFβ2 ELISA. TGFβ receptor type I inhibitor and MAPK inhibitor
were applied to address the involvement of TGFβ signalling and MAPK signalling in IL4-induced alternative
activation of microglia.
Results: TGFβ enhances IL4-induced microglia alternative activation by strongly increasing the expression of Arg1
and Ym1. This synergistic effect on Arg1 induction is almost completely blocked by the application of the MAPK
inhibitor, PD98059. Further, treatment of primary microglia with IL4 increased the expression and secretion of
TGFβ2, suggesting an involvement of endogenous TGFβ in IL4-mediated microglia activation process. Moreover,
IL4-mediated induction of Arg1 and Ym1 is impaired after blocking the TGFβ receptor I indicating that IL4-induced
microglia alternative activation is dependent on active TGFβ signalling. Interestingly, treatment of primary microglia
with TGFβ alone results in up regulation of the IL4 receptor alpha, indicating that TGFβ increases the sensitivity of
microglia for IL4 signals.
Conclusions: Taken together, our data reveal a new role for TGFβ during IL4-induced alternative activation of
microglia and consolidate the essential functions of TGFβ as an anti-inflammatory molecule and immunoregulatory
factor for microglia.
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Background
Microglia represent the resident immune cells of the
central nervous system (CNS) and account for approxi-
mately 12% of all cells in the brain [1]. As counterparts
of peripheral macrophages, microglia sense the brain
parenchyma for perturbations resulting from injury or
pathological conditions. Several CNS neurodegenerative
pathologies including Alzheimer’s disease (AD) [2-4],
multiple sclerosis (MS) [5,6] and Parkinson’s disease
(PD) [7,8] are characterised by a strong microglia reac-
tion that is, at least partially, responsible for the progres-
sive nature of these diseases.
Increasingly, studies have demonstrated that microglia,
like peripheral macrophages, exhibit two entirely func-
tional different activation states that are referred to as
classical and alternative activation. The classical activa-
tion of microglia (M1) is induced by Th1 cytokines, such
as IFNγ, IL1β, IL12, and IL6 as well as lipopolysacchar-
ide (LPS) and results in production and release of
pro-inflammatory cytokines such as tumour necrosis
factor-alpha (TNFα), IL6, matrix metalloproteinase
(MMP)-9, nitric oxide (NO) and reactive oxygen/nitro-
gen species (ROS) [9-11] which are involved in
inflammation-mediated neurotoxicity [12-14]. Whereas
alternative activation of microglia (M2) initiated by Th2
cytokines, such as IL4 and IL13, as well as IL10 and
TGFβ, results in up regulation of arginase-1 (Arg1),
Chitinase 3 like 3 (Ym1) and found in inflammatory
zone-1 (Fizz1), which are primarily associated with tissue
repair and extracellular matrix composition [3,11]. As
hypothesised by Town et al. these differently activated
microglia likely exist as a dynamic continuum in vivo,
with functions ranging from deleterious to beneficial
[15,16]. All these notions suggest that modulating
microglia activation states might be a potential thera-
peutic approach to different types of neurodegenerative
diseases including AD, MS, and PD.
Based on the M1 and M2 activation states, a more
detailed categorization of macrophage activation states has
recently been discussed. As suggested by Gordon and col-
leagues [11,17,18], alternative activation is only limited to
macrophages treated with IL4 or IL13 and is primarily
associated with injury resolution including tissue repair and
extracellular matrix reconstruction. While IL10 and TGFβ
promote a macrophage phenotype characterised by inflam-
mation resolution including inhibition of pro-inflammatory
cytokine production, modification of inflammatory signal-
ling pathways and increased expression of scavenger recep-
tors, thereby, promoting debris clearance. This type of
activated macrophage has been termed acquired deactiva-
tion [19-23]. Whereas IL10 and TGFβ induce acquired de-
activation, the acquired deactivation macrophages can
further produce IL10 and TGFβ in an autocrine manner
[3,24,25]. Regarding the immunoregulatory function of
IL10 and TGFβ produced by the acquired deactivation
macrophages, this phenotype of macrophages has been also
named as a regulatory macrophage by Mosser and Edwards
[24]. Although these studies promoted the knowledge of
microglia/macrophage activation phenotypes and their dis-
tinct functions, there is still no general agreement in the
field on the nomenclature and, more importantly, the inter-
action between different activation states of microglia/
macrophages is still poorly understood.
TGFβ is a multifunctional cytokine involved in a var-
iety of physiological and pathological conditions [26].
TGFβs bind to the TGFβ receptor type II, which recruits
and phosphorylates a type I receptor. The type I recep-
tor then phosphorylates Smad2/3, which further bind to
Smad4 to form a heteromeric complex that translocates
into the nucleus to regulate the expression of target
genes [27,28]. Next to the canonical Smad-dependent
pathway, TGFβs also signal via Smad-independent sig-
nalling cascades, including mitogen-activated protein
kinase signalling (MAPK) pathways [29].
In this study we used the microglial cell line BV2 and
primary microglia to investigate the role of TGFβ in
IL4-induced alternative activation, thereby illustrating
the interaction between different microglia/macrophage
activation states. For the first time, we provide evidence
that although TGFβ1 treatment alone is not able to in-
duce microglia, alternative activation, treated together
with IL-4, strongly enhances IL4-induced alternative
microglia activation. Arg1 and Ym1 expression was sig-
nificantly increased after co-treatment with IL4 and
TGFβ1. To our surprise, Arg1 and Ym1 expression
induced by IL4 treatment alone was significantly
impaired in the presence of the TGFβ receptor type I in-
hibitor. Further investigation revealed that IL4 treatment
alone increased microglial TGFβ2 expression and secre-
tion, which in turn might promote IL4-induced Arg1
and Ym1 expression. Moreover, we found TGFβ1 treat-
ment resulted in up regulation of the IL4 receptor alpha
(IL4Rα). Finally, we provide evidence that the Mitogen-
activated protein kinase (MAPK) pathway is essential for
TGFβ-mediated enhancement of Arg1 expression after
IL4 treatment in microglia.
Methods
Cytokines and reagents
All reagents for cell culture, namely Trypsin-EDTA 1×,
Hank’s balanced salt solution (BSS), Dubecco’s modified
Eagle medium (DMEM)-Ham’s F12, penicillin/streptomycin
(P/S) 100×, and fetal calf serum (FCS) were purchased
from PAA Laboratories (Cölbe, Germany). MAPK/ERK
(MEK) inhibitor PD98059 and poly-D-lysine were pur-
chased from Sigma-Aldrich (Deisenhofen, Germany). Re-
combinant murine IL4 and recombinant human TGFβ1
were purchased from PeproTech (Hamburg, Germany).
Zhou et al. Journal of Neuroinflammation 2012, 9:210 Page 2 of 14
http://www.jneuroinflammation.com/content/9/1/210
TGFβ receptor type I kinase inhibitor (TβKI) was
obtained from Merck Chemicals (Darmstadt, Germany).
Primary antibodies: anti-Arginase1, anti-IL4Rα, anti-
TGFβ2 and anti-Smad1/2/3 were purchased from
SantaCruz (Heidelberg, Germany). Phospho-Smad2-
Ser465/467 and phospho-Stat6-Tyr641 were obtained
from New England Biolabs (Frankfurt, Germany), Ym1
antibody was from StemCell Technologies (Grenoble,
France). GAPDH was purchased from Abcam (Cam-
bridge, UK). Goat anti-mouse Cy3, goat anti-rabbit Cy3
were from Dianova (Hamburg, Germany).
BV2 cell culture
The murine microglia cell line BV2 was maintained in
DMEM/F12 (PAA) supplemented with 10% heat-
inactivated FCS and 1% P/S. Cultures were kept at 37°C
in 5% CO2/95% humidified air atmosphere. Prior to
treatment cells were washed with PBS and serum-free
medium was added.
Primary microglia cultures
Whole brains obtained from P0/1 C57BL/6 mice were
washed twice with Hank’s BSS solution and vessels and
meninges were removed from brain surfaces under the
microscope. Cleaned brains were collected and enzyma-
tically dissociated with Trypsin-EDTA (1×) for 15 min-
utes at 37°C. An equal amount of ice-cold FCS, together
with DNase I (Roche Diagnostics, Mannheim, Germany)
at a final concentration of 0.5 mg/ml was added prior to
dissociation with wide- and narrow-bored polished Pas-
teur pipettes. Cells were then washed and single cells
were centrifuged, collected and suspended with
(DMEM)-Ham’s F12 medium containing 10% fetal bo-
vine serum (FBS) and 1% Penicillin/Streptomycin. Cell
suspensions were transferred to poly-D-lysine-coated tis-
sue culture flasks with a density of 2 brains/75 cm2 flask.
Cultures were maintained in a humidified 5% CO2/95%
air atmosphere at 37°C. At day in vitro (DIV) 2 and 3,
cultures were washed twice with pre-warmed phosphate-
buffered saline (PBS) and fresh culture medium was
added. After 10 to 14 days in culture, microglia were
shaken off from adhesive grown astroglia by shaking at
approximately 250 to 300 rpm for 1 hour. Isolated
microglia were plated into various dishes or plates and
treated with proper factors, according to different ex-
perimental purposes.
Immunocytochemistry
Microglia were plated on glass coverslips and were fixed
after treatment with 4% paraformaldehyde (PFA) for
15 minutes at room temperature. After blocking with
PBS containing 10% normal goat serum and 0.1%
TritonX-100 (Roche, Mannheim, Germany) for 1 hour at
room temperature, cells were incubated with primary
antibodies at 4°C overnight, followed by an incubation
with corresponding Cy3-conjugated secondary anti-
bodies (goat anti-mouse Cy3 1:100, goat anti-rabbit Cy3
1:100). Nuclei were counterstained using 40,6-diamidino-
2-phenylindole (DAPI, Roche). Phase contrast and fluor-
escence images were captured using the Leica AF6000
imaging system (LEICA, Wetzlar, Germany).
Protein isolation and western blotting
Total proteins were isolated from primary microglia and
BV2 cells after washing with PBS and incubation with
ice-cold mammalian protein extraction reagent (M-PER,
Thermo Scientific, Bonn, Germany) plus Complete Pro-
tease Inhibitor (Roche) with gentle up and down shaking
for 5 minutes. The supernatant as well as debris were
collected, and centrifuged at 14,000 rpm for 8 minutes
to obtain the supernatant, which contains proteins. After
determination of protein concentrations, 10–15 μg total
proteins were loaded onto 10 to 12% SDS gels. After
electrophoresis, proteins were transferred to polyvinyli-
dene difluoride (PVDF) membranes (Immobilon, Mili-
pore, Schwalbach, Germany). Blots were blocked with
5% non-fat dry milk in Tris-buffered saline containing
0.05% Tween-20 (TBST) for 1 h and incubated with pri-
mary antibodies overnight at 4°C. Primary antibodies
against Arginase-1 (rabbit polyclonal, 1:1000, Santa-
Cruz), phospho-Smad2 (Ser465/467) (rabbit, 1:1000,
Cell Signaling), phospho-Stat6 (Tyr641) (rabbit, 1:1000,
Cell Signaling), IL4Rα (mouse, 1:1000, SantaCruz),
TGFβ2 (rabbit polyclonal, 1:1000, SantaCruz), Ym1
(rabbit polyclonal, 1:1000, StemCell Technologies) and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
(mouse monoclonal, 1:10,000, Abcam, Cambridge, UK)
were used. After incubation with goat anti-rabbit or goat
anti-mouse IgG horseradish peroxidase (HRP)-linked anti-
bodies (1:10,000, Cell Signaling), blots were developed
using Western LightningW Plus-ECL, Enhanced Chemilu-
minescence Substrate (Perkin-Elmer, Rodgau, Germany).
Signals were captured on Amersham Hyperfilm™ECL (GE
Healthcare, München, Germany). Band intensities were
evaluated using the software FlourChem 8800 (Alpha
Innotech, Biozym, Olendorf, Germany).
RNA isolation and quantitative RT-PCR
RNA was isolated from BV2 and primary microglial cells
with the RNeasy kit (Qiagen, Hilden, Germany), accord-
ing to the manufacturer’s instructions. RNA was reverse
transcribed to cDNA with the GeneAmp RNA PCR
Core Kit (Applied Biosystems, Darmstadt, Germany).
Quantitative RT-PCR (qRT-PCR) analysis was performed
with the MyiQ™ (BIO-RAD, München, Germany) and
the Quantitect SYBR Green PCR Kit (Applied Biosys-
tems) with 1 μl of cDNA template in a 25 μl reaction
mixture. Results were analysed with the Bio-Rad iQ5
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Opitcal System Software and the comparative CT
method. Data are expressed as 2-ΔΔCT for the experimen-
tal gene of interest normalized to the housekeeping
gene (GAPDH) and presented as fold change relative to
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Characterisation of TGFβ secretion
Primary microglia were treated with or without IL4
(10 ng/ml) in serum-free DMEM-Ham’s F12 medium for
24 hours. Conditioned medium was collected for the
mink lung epithelial cell (MLEC) assay and ELISA. The
MLEC assay is widely used to measure the amount of
TGFβs in conditioned medium. The principal is that the
MLECs containing a luciferase reporter under the con-
trol of a TGFβ-responsive truncated plasminogen activa-
tor inhibitor (PAI)-promoter are able to generate
luciferase with a TGFβs dose-dependent manner. Since
the MLECs only response to the activated TGFβs, in
order to detect the latent part of TGFβs, the conditioned
medium has to be acidification first to convert latent
TGFβs into activated ones. To evaluate the levels of
released TGFβs after IL4 treatment, the MLEC assay
was performed as described by Abe et al. [30]. Briefly,
MLECs were placed into 96-well plates at the density of
1.5 × 104 cells per well and treated with collected condi-
tioned medium either with or without acidification with
1 M HCL and pH adjustment with NaOH (to activate
latent TGFβs) as well as the standard mediums contain-
ing different contractions of recombinant TGFβ for
16 hours. Cells were washed with PBS and total pro-
teins were extracted using lysis buffer (Tropix, Applied
Biosystems). The luciferase activity was analysed in
duplicates using a luminometer (LumatB5076, Berthold,
Bad Wildbad, Germany).
Direct enzyme-linked immunosorbent assay for TGFβ2
detection
Conditioned media collected from primary microglia
after treatment with and without IL4 (10 ng/ml), as well
as diluted recombinant human TGFβ2 (2000, 1000, 500,
250, 125, 62.5 and 31.25 pg, R&D Systems, Wiesbaden-
Nordenstedt, Germany) standard solutions, were added
into ELISA plates (NUNC, Wiesbaden, Germany) and
incubated overnight at 4°C. After washing with washing
buffer (0.05% Tween-20 in PBS) and blocking with 1%
BSA in PBS for 2 hours at 37°C, the plates were incu-
bated with anti-TGFβ2 (Santa Cruz) primary antibodies
overnight at 4°C. Followed by washing and incubation
with Biotin-linked anti-rabbit secondary antibodies for
2 hours at 37°C, plates were incubated with ABC-
solution (Vectashield, BIOZOL, Eching, Germany).
Colour reaction was performed using 2, 20-azino-bis (3-
ethylbenzothiazoline-6-sulphonic acid) substrate (ABTS,
Sigma-Aldrich, Deisenhofen, Germany) for 30 minutes
in the dark. Finally, absorbance was detected using an
FC Multiskan plate reader (Thermo Fischer, Bonn, Ger-
many) at the absorption of 405 nm.
Cytokine array
For the analysis of IL4 release, supernatant from un-
treated and TGFβ1-treated primary microglia was ana-
lysed using the Proteome Profiler™ Array Mouse
Cytokine Array Panel A (R&D Systems, Wiesbaden-
Nordenstedt, Germany) according to the manufacturer’s
instructions. Briefly, equal amounts of primary miroglia
cells were incubated for 24 hours in the presence or ab-
sence of TGFβ1 and media were collected. Cytokine array
membranes were incubated with cell culture supernatants
at 4°C overnight with gentle shaking. Membrane signals
were developed using Western LightningW Plus-ECL,
Enhanced Chemiluminescence Substrate (Perkin-Elmer,
Germany) and signals were captured on Amersham
Hyperfilm™ ECL (GE Healthcare).
Statistical procedures
The data were expressed as means ± standard error (SE).
Statistical significance between multiple groups was
compared by one-way analysis of variance (ANOVA) fol-
lowed by an appropriate multiple comparison test. Two-
group analysis was performed using the Student’s t-test.
P-Values < 0.05 were considered statistically significant.
All statistical analyses were performed using GraphPad
Prism4 software (GraphPad Software Inc.).
Results
TGFβ1 enhances IL4-induced alternative microglia
activation
To investigate the influence of TGFβ1 on IL4-induced
microglia-alternative activation, primary microglia were
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treated either with IL4 (10 ng/ml), TGFβ1 (1n g/ml) or
with a combination of both factors for 24 hours. As a
crude readout for microglia activation, the morphology
change of microglia was analysed after treatment. Treat-
ment with IL4 or TGFβ1 alone for 24 hours resulted in
morphology changes in BV2 cells (data not shown) and
primary microglia towards a more ramified phenotype.
This extent of morphological change was remarkably
increased when the cells were treated with IL4 and
TGFβ1 together (Figure 1A). As the morphological
change could not always precisely reflect the activation
states, the assessment of the alternative activation still
relied on the molecule markers such as Arg1 and Ym1.
Therefore, the expression of Arg1 and Ym1 were ana-
lysed. Immunofluorescence staining demonstrated
increased Arg1 staining intensity after IL4 treatment.
Figure 1 TGFβ1 enhances IL4-induced alternative activation of microglia. (A) Primary cultured microglial cells changed their morphology
from round-shaped into ramified after treated with IL4 (10 ng/ml) and TGFβ1 (1 ng/ml) for 24 hours. This cellular morphological change was
enhanced when microglia were co-treated with IL4 and TGFβ1. (B) Immunofluorescence staining for Arg1 demonstrated increased staining
intensity for Arg1 after treatment with IL4 or TGFβ alone. Combined treatment with IL4 and TGFβ1 strongly enhanced Arg1 immunoreactivity.
Scale bars indicate 100 μm. Quantitative RT-PCR showed increased Arg1 (C) and Ym1 (D) mRNA levels in primary microglia after IL4 treatment.
Co-treatment with IL4 and TGFβ1 for 24 hours significantly increased Arg1 and Ym1 mRNA levels in primary microglia. (E) Western blotting
revealed increased Arg1 and Ym1 protein levels in primary microglia after treatment with IL4. Again, co-treatment with IL4 and TGFβ1 increased
the protein levels of Arg1 and Ym1. Representative western blot results from at least three independent experiments are shown. GAPDH was
used as control for equal protein loading. (F) Densitometric evaluation of Arg1 and Ym1 band intensities and statistical analysis. Data are given as
means ± standard error from three independent experiments: *P< 0.05, **P< 0.01, ***P< 0.001 (one-way analysis of variance).
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Combination of IL4 and TGFβ1 further increased the
staining intensity (Figure 1B). Using quantitative RT-
PCR the up regulation of Arg1 and Ym1 was deter-
mined. A significant increase in Arg1 and Ym1 RNA
levels was observed after treatment with IL4 alone.
TGFβ1 treatment alone did not result in increased Arg1
and Ym1 mRNA levels (P > 0.05). However, treatment
with IL4 and TGFβ1 resulted in significant increase of
Arg1 and Ym1 RNA levels (P < 0.001) compared to IL4
treatment alone (Figure 1C, D). As shown in Figure 1E
and F, IL4 treatment significantly increased Arg1 and
Ym1 protein levels in primary microglia (P < 0.05).
TGFβ1 slightly increased Arg1 and Ym1 protein levels
in primary microglia, without reaching significant differ-
ences compared to control (P > 0.05). Combination of
IL4 and TGFβ1 significantly increased IL4-induced Arg1
and Ym1 protein levels in primary microglia (P < 0.05).
IL4-induced Arg1 and Ym1 upregulation is dependent on
TGFβ signalling
In order to address whether endogenous TGFβ signalling
is involved in IL4-induced alternative microglia activa-
tion, primary microglia were treated with the combin-
ation of IL4 and TGFβ type I receptor kinase inhibitor
IV (TβKI). We found expression of Arg1 and Ym1
induced by IL4 were partially impaired by TβKI. As is
shown in Figure 2, primary microglia were treated either
with IL4 (10 ng/ml) or IL4 (10 ng/ml) together with
TβKI (2 μM/ml) for 24 hours, there the mRNA and pro-
Figure 2 Arg1 and Ym1 expression induced by IL4 was blocked in the presence of a TGFβ receptor type I inhibitor. Primary microglia
were treated with IL4 (10 ng/ml) combined either with or without TGFβ receptor type I kinase inhibitor IV (TβKI, 2 μM) for 24 hours. RNA and
proteins were isolated for quantitative RT-PCR and western blotting, respectively. Quantitative RT-PCR shows that IL4 treatment significantly
increased Arg1 (A) and Ym1 (B) mRNA levels (P< 0.001) which was partially blocked by co-treatment with TβKI (P< 0.01). Western blotting (C)
shows Arg1 and Ym1 protein levels in primary microglia after different treatments, which were quantified by densitometric analysis, and
normalized to Gapdh (D). IL4 treatment significantly increased Arg1 and Ym1 protein levels in primary microglia (P< 0.01), which was significantly
blocked by TβKI in microglia (P< 0.05). Data are presented as mean± standard error from three independent experiments: *P< 0.05, **P< 0.01,
***P< 0.001 (one-way analysis of variance).
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qRT-PCR revealed that Arg1 and Ym1 mRNA up regula-
tion after IL4 treatment was significantly reduced by co-
treatment with TβKI (Figure 2A, B). Western blotting
results demonstrate that Arg1 and Ym1 protein levels in
primary microglia were increased after IL4 treatment
and significantly decreased in the presence of TβKI
(Figure 2C, D). Similar results have been achieved from
BV2 cells (data not shown). All these data indicate that
IL4-induced Arg1 and Ym1 expression is at least par-
tially dependent on endogenous TGFβ signalling in
microglia after IL4 treatment.
IL4-treated microglia increase TGFβ2 expression and
secretion
To investigate the endogenous TGFβs expression and se-
cretion form microglia after IL4 treatment, primary
microglia were treated with or without IL4 (10 ng/ml)
for 24 hours. The cells were harvested for mRNA extrac-
tion and qRT-PCRs for different isoforms of TGFβ were
performed. Quantitative RT-PCR demonstrates that
among all TGFβ isoforms, only TGFβ2 mRNA was sig-
nificantly up regulated after IL4 treatment (Figure 3A,B,
C). Since the TGFβ receptor inhibitor used above is not
specific for TGFβ1, 2 or 3, in addition to the blockage of
TGFβ1, 2, 3, it also inhibits Activin and Nodal signalling.
Therefore, the mRNA levels of the Activin A, Activin B,
and Nodal were also analysed using qRT-PCR but were
not changed after IL4 treatment (data not shown). The
protein levels of intracellular TGFβ2 were significantly
increased (P= 0.028) after treatment with IL4
(Figure 3D). Since endogenous TGFβ2 in primary micro-
glial cells is up regulated after IL4 treatment, we further
addressed whether TGFβ secretion from IL4-treated
microglia is also increased. Therefore, the conditioned
media from IL4-treated (MCM-IL4) as well as non-
treated microglial cells (MCM) were harvested after
24 hours and the MLEC assay was performed to monitor
TGFβ secretion. Quantification of TGFβ-induced inten-
sity of luciferase shows that primary microglia secreted
TGFβ under basal conditions and most of this was in a
latent and inactive state. IL4 treatment significantly
increased latent TGFβ secretion (Figure 3E). Since the
MLEC assay is not specific for different TGFβ isoforms,
based on the qRT-PCR results we used a direct ELISA
for TGFβ2 and demonstrated a significant increase in
TGFβ2 secretion after IL4 treatment (Figure 3F).
TGFβ1 increases IL4Rα expression in primary microglia
Based on our observation that TGFβ1 also enhances the
IL13-induced Arg1 up regulation in BV2 cells and
primary microglia (data not shown), as well as the know-
ledge that IL4 and IL13 share the IL4Rα as a common
receptor, which promotes phosphorylation of the tran-
scription factor Stat6 that finally induces Arg1
expression [11,31], we analysed whether IL4Rα is regu-
lated by TGFβ1. Primary microglia were treated with
TGFβ1 (1 ng/ml) for different time points and RNA and
proteins were isolated. The qRT-PCR results demon-
strate that TGFβ1 treatment significantly increased the
mRNA levels of IL4Rα after 2 and 4 hours, with the
peak at 2 hours. From 6 to 24 hours the levels decreased
and finally returned to basal levels at 24 hours after
TGFβ1 treatment (Figure 4A). Western blotting con-
firmed the TGFβ1-mediated up regulation of IL4Rα.
IL4Rα protein levels increased after treatment with
TGFβ1 reaching the maximum from 6 to 12 hours. After
treatment for 24 hours, IL4Rα protein levels returned to
basal levels (Figure 4B). Immunostaining for IL4Rα after
treatment with TGFβ1 for 6, 12 and 24 hours showed a
similar pattern. IL4Rα staining intensity was increased 6
and 12 hours after treatment with TGFβ1. After
24 hours, the IL4Rα signal was comparable to the con-
trol condition (Figure 4C). We further analysed whether
TGFβ1 has an effect on microglial IL4 expression and
release. As shown in Figure 4D and E, IL4 mRNA levels
were not significantly changed after TGFβ1 treatment
for 24 hours. Using a mouse-specific cytokine array, we
revealed that primary microglia release very low levels of
IL4 and treatment of primary microglia with TGFβ1 did
not result in any changes in IL4 release after 24 hours.
These data suggest that the enhancement of Arg1 and
Ym1 expression by TGFβ in IL4-treated microglia might,
at least partially, be mediated by increasing IL4Rα ex-
pression, thus, enhancing the microglial sensitivity to
IL4 signals.
Mitogen-activated protein kinase mediates TGFβ1-enhanced
Arg1 expression in IL4-treated primary microglia
To investigate the pathways involved in TGFβ1-
mediated enhancement of IL4-induced Arg1 expression,
the TGFβ/Smad and the IL4/Stat6 signalling pathways
were analysed by monitoring Smad2/3 nuclear accumu-
lation and phosphorylation of Smad2 and Stat6, respect-
ively. Whereas treatment of primary microglia with
TGFβ1 resulted in increased nuclear accumulation of
Smad2/3, IL4 treatment failed to induce nuclear accu-
mulation of Smad2/3 (Figure 5A). Immunoblotting
against phospho-Smad2 and phospho-Stat6 revealed that
TGFβ1 exclusively increased the levels of phosphory-
lated Smad2 and failed to increase the levels of phos-
phorylated Stat6. Vice versa, IL4 treatment resulted in
increased levels of phospho-Stat6, whereas phosphoryl-
ation of Smad2 was not observed after treatment with
IL4 for 1 and 2 hours (Figure 5B).
MAPK has been shown to be activated in microglia
after TGFβ1 treatment [32]. To analyse the role of
MAPK signalling on TGFβ1-mediated enhancement of
IL4-induced Arg1 expression, BV2 cells and primary
Zhou et al. Journal of Neuroinflammation 2012, 9:210 Page 7 of 14
http://www.jneuroinflammation.com/content/9/1/210
Figure 3 Treatment of microglia with IL4 increased TGFβ2 expression and secretion. Primary microglia were treated with or without IL4
(10 ng/ml) for 24 hours. Total mRNA and proteins were isolated from the cells for RT-PCR and western blotting, respectively. Conditioned
medium from IL4-treated microglia (MCM-IL4) as well as non-treated microglia (MCM) was collected and the mink lung epithelial cell (MLEC)
assay and enzyme-linked immunosorbent assay (ELISA) were performed. Quantitative RT-PCR for TGFβ1 (A), TGFβ2 (B) and TGFβ3 (C) revealed
increased TGFβ2 expression after IL4 treatment. Intracellular TGFβ2 protein levels were significantly increased (P< 0.05) in primary microglia after
treatment with IL4 (D). MLEC assay (E) shows that primary microglia secreted a certain amount of inactive TGFβ, which was significantly increased
by IL4 treatment (P< 0.01). Direct TGFβ2 ELISA (F) showed that TGFβ2 secretion was significantly increased after IL4 treatment (P< 0.05). All
experiments were repeated at least three times. Data are presented as mean± standard error: *P< 0.05, **P< 0.01, ***P< 0.001(Student’s t-test).
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microglia were treated with IL4, TGFβ1 and IL4/TGFβ1
in the absence or presence of the MEK1/2 inhibitor
PD98059 for 24 hours. Western blotting results from
BV2 cells showed that IL4 treatment alone increased
Arg1 protein levels, which was partially inhibited in the
presence of PD98059. TGFβ1 and IL4 co-treatment
increased IL4-induced Arg1 protein levels and the
MEK1/2 inhibitor PD89059 partially blocked the
TGFβ1-mediated increase in Arg1 protein levels
(Figure 6A). Using primary microglia we confirmed the
results obtained with BV2 cells. Treatment with IL4 sig-
nificantly increased the protein levels of Arg1. Interest-
ingly, in the presence of PD89059, IL4 failed to increase
the protein levels of Arg1. Combination of IL4 and
TGFβ1 dramatically increased the protein levels of Arg1
compared to IL4 treatment alone. However, in the pres-
ence of the MEK1/2 inhibitor PD89059, TGFβ1-
enhanced Arg1 up regulation was significantly impaired
and the amount of Arg1 was similar to the levels after
treatment with IL4 alone (Figure 6B, C). These data
demonstrate that TGFβ1-activated MAPK signalling is
essential for TGFβ1-mediated enhancement of IL4-
induced Arg1 expression in microglia.
Discussion
In this study we demonstrate for the first time that
TGFβ enhances the IL4-induced alternative activation of
microglia. Using Arg1 and Ym1 as established markers
for alternative activation [3,11] we provide evidence that
IL4-mediated up-regulation of Arg1 and Ym1 is signifi-
cantly enhanced in the presence of TGFβ1. Further, IL4
treatment resulted in increased expression and secretion
of TGFβ2, whereas TGFβ treatment of microglia
increased the expression of the IL4Rα. Moreover,
Figure 4 TGFβ1 up regulates the IL4Rα. Primary microglia were treated with TGFβ1 (1 ng/ml) for different time points and the cells were
either harvested for analysing IL4Rα mRNA and protein levels, or fixed with 4% paraformaldehyde (PFA) for IL4Rα immunostaining. Quantitative
RT-PCR showed that treatment with TGFβ1 increased IL4Rα mRNA levels starting after 1 hour and peaking at around 2 hours. Afterwards mRNA
levels decreased again and returned to basal levels at 24 hours (A). Western blotting showed IL4Rα protein expression starting to increase after
treatment with TGFβ1 for 1 hour and peaking at around 6 to 12 hours after treatment (B). After treatment with TGFβ1 for 6 and 12 hours, IL4Rα
immunoreactivity (red) was increased and cell morphology changed towards a ramified phenotype compared to control cells. After 24 hours, the
IL4Rα immunoreactivity (red) was decreased but the cells still presented a ramified shape with long processes (C). Scale represents 20 μm.
Treatment of primary microglia with TGFβ1 (n = 5) had no effect on IL4 mRNA levels (D). Analysis of TGFβ1-mediated changes in microglial
cytokine release (n = 2) demonstrated no differences in IL4 levels after TGFβ1 treatment (E). Data (A,B, D) are presented as means ± standard error:
**P< 0.01, ***P< 0.001 (one-way analysis of variance).
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blocking the TGF-β receptor type I resulted in signifi-
cantly impaired Arg1 and Ym1 up-regulation after IL4
treatment. Finally, we demonstrate that TGFβ-mediated
enhancement of Arg1 expression in microglia is
dependent on the MAP kinase pathway.
In parallel to transcriptional regulation of microglia
markers, the morphological changes are used to discrimin-
ate between different activation states in vivo and in vitro.
In the resting or inactive state, microglia present a rami-
fied morphology with several processes, while stimulation
with classical activation factors such as LPS or IFNγ
results in retraction of microglial processes and develop-
ment of an amoeboid phenotype [33,34]. Although
changes in morphology also suggest changes in the func-
tional states of microglia, the morphology alone cannot be
used to predict a functional outcome. Therefore, we ana-
lysed Arg1 and Ym1 as markers for macrophage and
microglia alternative activation. Arg1 has been shown to
be localised in the cytoplasm of hepatocytes where it is
involved in nitrogen elimination by catalysing arginine hy-
drolysis to urea and ornithine [11,35]. Unlike the constitu-
tively expressed Arg1 in the liver, Arg1 in macrophages
and microglia is induced by exogenous stimuli including
the Th2 cytokines IL4 and IL13 [36,37]. Arg1 inhibits NO
production by competing with the inducible nitric oxide
synthase (iNOS) for the common substrate L-arginine
[38]. On the other hand, the production of ornithine can
be used to generate polyamines, glutamate, and proline,
the latter being a substrate for the formation of extracellu-
lar matrix proteins such as collagen [38-40]. Interestingly,
apart from involvement in the regulation of wound healing
and fibrosis [41,42], Arg1 can directly support neuron sur-
vival [43]. Next to Arg1, Ym1 is another established mar-
ker for microglia alternative activation [2,44]. Ym1 is a
heparin/heparin sulphate-binding lectin that is transiently
expressed during inflammation [44] and although the pre-
cise functions of Ym1 remain elusive, recent reports have
suggested an involvement in tissue remodelling and regu-
lation of inflammation [45,46].
TGFβ has been shown to either up-regulate Arg1 ex-
pression or increase the Arg1 enzymatic activity in a cell
type-dependent manner. Whereas TGFβ treatment
results in increased expression of Arg1 in fibroblasts and
epithelial cells [47-49], TGFβ strongly increases enzyme
activity in macrophages [50,51]. In this study we demon-
strate that TGFβ1 alone is not able to significantly in-
crease expression of Arg1 and Ym1 in microglia.
However, in the presence of IL4, TGFβ1 significantly
enhanced IL4-induced Arg1 and Ym1 expression, which
indicates the potential role of TGFβ in CNS tissue repair
Figure 5 Direct interactions were not observed between the TGFβ/Smad signalling pathway and the IL4/Stat6 signalling pathways.
Primary microglial cells were treated with either with IL4 (10 ng/ml), TGFβ1 (1 ng/ml) alone or together for 1 and 2 hours. The cells were either
fixed with 4% paraformaldehyde (PFA) for pSmad2/3 immunostaining or harvested for testing pStat6 and pSmad2 levels. The treatment of TGFβ1
alone or TGFβ1 combining IL4-induced pSmad2/3 nuclear translocation both at 1 and 2 hours while IL4 treatment alone was not able to induced
pSmad2/3 nuclear translocation (A). Western blotting showed that IL4 treatment alone exclusively induced Stat6 phosphorylation but not Smad2
phosphorylation after 1 and 2 hours, while TGFβ1 treatment alone or TGFβ1 in combination with IL4 only, induced Smad2 phosphorylation but
not Stat6 phosphorylation (B).
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and neurorestoration by modulating alternative activa-
tion of microglia.
To understand the mechanisms behind this
phenomenon we addressed the question of whether
TGFβ interferes with the IL4 signalling pathway. We
demonstrated that TGFβ1 treatment alone up regulated
the common receptor for IL4 and IL13, IL4Rα, both at
mRNA and protein levels in a time-dependent manner.
Opposite to the effect of TGFβ1 on IL4Rα expression,
IL4 treatment alone reduced IL4Rα expression with
treatment time (data not shown). Further, we observed
that TGFβ1 was able to enhance the expression of Arg1
induced by IL13 (data not shown) and IL4. These data
indicate that the synergistic effect of TGFβ1 and IL4 on
the expression of Arg1 might partially be mediated by
enhanced IL4Rα expression after TGFβ1 treatment,
thereby increasing the sensitivity of microglia for IL4.
IL4 signalling is further propagated by phosphorylation
of the transcription factor Stat6 [11,31]. Analysis of Stat6
phosphorylation revealed that TGFβ1 failed to induce
Stat6 phosphorylation. Moreover, IL4 was not able to in-
duce Smad2 phosphorylation in microglia, indicating
that the synergistic effect of TGFβ1 and IL4 on the ex-
pression of Arg1 could not be explained by the direct
interaction of the TGFβ/Smad and IL4/Stat6 signalling
pathways. Therefore, we further investigated if a TGFβ-
induced Smad-independent pathway, the MAPK path-
way, is involved in this synergistic effect. By performing
a pharmaceutical blockage of the TGFβ-induced MAPK
pathway using the MEK1/2 inhibitor PD98059, we could
show that the Arg1 protein expression, not only induced
by TGFβ1 and IL4 co-treatment but also induced by IL4
treatment alone, were significantly inhibited in the pres-
ence of PD98059. These data clearly demonstrate that
TGFβ signalling is involved in IL4-induced microglia al-
ternative activation and an essential role of TGFβ-
mediated MAPK pathway in the enhancement of IL-4
induced microglia alternative activation by TGFβ
signalling.
We observed that IL4 treatment of microglia lead to
up regulation of TGFβ2, whereas the mRNA levels of
TGFβ1 and TGFβ3 were not changed after IL4 treat-
ment. TGFβ2 levels were significantly increased in the
supernatants of IL4-treated microglia. Although most of
the secreted TGFβ2 was in a latent and inactive form, a
small proportion of bioactive TGFβ2 seems to be suffi-
cient to support IL4-induced up regulation of Arg1 and
Ym1. However, microglia express several factors and
enzymes that are capable of activating latent TGFβs, such
as integrins, plasminogen, MMP2 and thrombospondin-
1 (unpublished data). Moreover, microglia also express
extracellular matrix components in vitro that might
bind TGFβ. This amount of bound, and probably acti-
vated, TGFβ will escape all analyses of the microglial
supernatant, but is likely to activate TGFβ signalling in
these cells.
It is widely accepted that TGFβ is involved in the
down regulation of microglia classical activation. TGFβ1
reduces reactive oxygen species (ROS) induced by LPS
and suppresses the IFNγ-induced expression of MHC II
and the production of cytokines, IL1, IL6, and TNF-
alpha production in activated microglia [52,53]. TGFβ
also prevents IL1β-induced microglial activation [54].
Although the anti-inflammatory role of TGFβ has been
widely accepted, it is still quite ambiguous whether this
effect is beneficial or detrimental in terms of different
CNS diseases. Whereas TGFβ1 has protective and bene-
ficial functions in cerebral ischaemia [55], it promotes
Figure 6 TGFβ1-mediated enhancement of IL4-induced Arg1
expression is dependent on the mitogen-activated protein
(MAP) kinase pathway. BV2 cells and primary microglia were
treated with IL4 (10 ng/ml), TGFβ1 (1 ng/ml) and IL4/TGFβ1 in the
presence or absence of the MAP kinase inhibitor PD98059 (10 μM)
for 24 hours. Total proteins were isolated and used for
electrophoresis and western blotting. Arg1 protein levels were
analysed by densitometric evaluation and normalised to GAPDH.
The expression levels of Arg1 after co-treatment with IL4 and TGFβ1
were reduced in the presence of PD98059 in both BV2 (A) and
primary microglia (B). Quantification of Arg1 expression levels in
primary microglia after different treatments (C). Data are presented
as means ± standard error from three independent experiments:
**P< 0.01, ***P< 0.001 (two-way analysis of variance).
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the deposition of amyloid-beta plaques in models of Alz-
heimer’s disease [56]. Interestingly, Town and colleagues
have demonstrated that blocking of TGFβ/Smad signalling
almost completely abrogated the plaque formation in
transgenic mice overexpressing mutant human amyloid
precursor protein [57]. These results underline the im-
portance of a tight temporal and spatial regulation of in-
nate immune responses and further demonstrate the
necessity to enhance our knowledge of the pathological
conditions under which TGFβ-mediated regulation of in-
flammation is beneficial or detrimental.
Whereas TGFβ induces acquired deactivation, the
acquired deactivation macrophages also produce TGFβ
in an autocrine manner [3,24,25]. Next to down regulat-
ing the classical activation of microglia, here we show,
for the first time, that the TGFβ also enhances IL4-
induced microglia alternative activation in vitro, which
broadens the knowledge of interactions among different
microglia activation states. Similar functions have been
shown for another immunoregulatory cytokine, IL10. For
example, IL10 is able to impair IFNγ-induced macro-
phage classical activation [58], increase arginase activities
[59], and further enhance IL4-induced Arg1 expression,
probably by increasing IL4Rα expression [60]. Findings
of this work and previous studies suggest an interaction
and dynamic change between different microglia activa-
tion states. TGFβ might serve as a gatekeeper to inhibit
classical activation and promote alternative activation of
microglia. The data presented throughout this study con-
firm the role of TGFβ as an anti-inflammatory molecule
and broaden its functions as an enhancer of microglia
alternative activation, thereby regulating microglia-
mediated neuroregeneration and neurorestoration in
inflammatory CNS diseases.
Conclusions
Here we show, for the first time, that TGFβ1 syner-
gises IL4 in the induction of microglia alternative acti-
vation. We demonstrate that IL4 treatment increased
the expression and secretion of TGFβ2 in primary
microglia and that IL4-induced up regulation of Arg1
and Ym1 is dependent on active TGFβ signalling.
Finally, we provide evidence that MAPK signalling is
involved in TGFβ-mediated enhancement of IL4-
induced microglia alternative activation. Figure 7 shows
a proposed model for the role of TGFβ in microglia al-
ternative activation. Our findings provide novel insights
into the molecular mechanisms of IL4-induced micro-
glia alternative activation, and further enhance our
knowledge of TGFβ-mediated modulation of microglial
functions.
Abbreviation
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